Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases

Clinical and Experimental Metastasis

Volumn 25, Issue 4, 2008, Pages 377-388

  Morrissey, Colm ^a,b   True, Lawrence D ^c   Roudier, Martine P ^a   Coleman, Ilsa M ^d   Hawley, Sarah ^d   Nelson, Peter S ^d   Coleman, Roger ^d   Wang, Ya Chun ^a   Corey, Eva ^a   Lange, Paul H ^a   Higano, Celestia S ^c   Vessella, Robert L ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Angiogenesis; Bone; Metastasis; Microvessel density; Prostate cancer

Indexed keywords

ANGIOPOIETIN 2; BLOOD CLOTTING FACTOR 13A; EPHRIN A1; FIBRINOGEN; FIBULIN; HEPSIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN PAI RBP 1; RNA BINDING PROTEIN; SIALOPROTEIN; UROKINASE;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD CLOTTING; BONE METASTASIS; CLINICAL ARTICLE; DNA MICROARRAY; FIBRINOLYSIS; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LYMPH NODE METASTASIS; MICROVASCULATURE; PROSTATE CANCER; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ANGIOPOIETIN-1; ANGIOPOIETIN-2; BONE AND BONES; CALCIUM-BINDING PROTEINS; FACTOR VIIIA; GENE EXPRESSION PROFILING; HUMANS; LIVER; LYMPHATIC METASTASIS; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTATIC NEOPLASMS; RNA-BINDING PROTEINS; URINARY PLASMINOGEN ACTIVATOR;

EID: 44449108773     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10585-007-9116-4     Document Type: Article

References (49)

1. Shah RB, Mehra R, Chinnaiyan AM et al (2004) Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 64:9209-9216
2. Roudier MP, True LD, Higano CS et al (2003) Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 34:646-653
3. Roudier MP, Corey E, True LD et al (2004) Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases. Cancer Treat Res 118:311-339
4. Olson KB, Pienta KJ (1999) Pain management in patients with advanced prostate cancer. Oncology-New York 13:1537-1549
5. Lange PH, Vessella RL (1998) Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev 17:331-336
6. Ohta S, Wada H, Nakazaki T et al (2002) Expression of tissue factor is associated with clinical features and angiogenesis in prostate cancer. Anticancer Res 22:2991-2996
7. Koeneman KS, Yeung F, Chung LW (1999) Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39:246-461
8. Lind AJ, Wikstrom P, Granfors T et al (2005) Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer. Prostate 62:394-399
9. Wikstrom P, Stattin P, Franck-Lissbrant I et al (1998) Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 37:19-29
10. Ferrer FA, Miller LJ, Andrawis RI et al (1998) Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 51:161-167
11. Ribatti D (2004) The involvement of endothelial progenitor cells in tumor angiogenesis. J Cell Mol Med 8:294-300
12. Baluk P, Hashizume H, McDonald DM (2005) Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 15:102-111
13. McDonald DM, Choyke PL (2003) Imaging of angiogenesis: from microscope to clinic. Nat Med 9:713-725
14. Wikstrom P, Lissbrant IF, Stattin P et al (2002) Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 51:268-275
15. Anilkumar G, Barwe SP, Christiansen JJ et al (2006) Association of prostate-specific membrane antigen with caveolin-1 and its caveolae-dependent internalization in microvascular endothelial cells: implications for targeting to tumor vasculature. Microvasc Res 72:54-61
16. Hawkins V, Doll D, Bumgarner R et al (1999) PEDB: the prostate expression database. Nucleic Acids Res 27:204-208
17. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98:5116-5121
18. Carlinfante G, Vassiliou D, Svensson O et al (2003) Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metastasis 20:437-444
19. Waltregny D, Bellahcene A, de Leval X et al (2000) Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. J Bone Miner Res 15:834-843
20. Godyna S, Diaz-Ricart M, Argraves WS (1996) Fibulin-1 mediates platelet adhesion via a bridge of fibrinogen. Blood 88:2569-2577
21. Sheng S (2001) The urokinase-type plasminogen activator system in prostate cancer metastasis. Cancer Metastasis Rev 20:287-296
22. Heaton JH, Dlakic WM, Dlakic M et al (2001) Identification and cDNA cloning of a novel RNA-binding protein that interacts with the cyclic nucleotide-responsive sequence in the Type-1 plasminogen activator inhibitor mRNA. J Biol Chem 276:3341-3347
23. Moran P, Li W, Fan B et al (2006) Pro-urokinase-type plasminogen activator is a substrate for hepsin. J Biol Chem 281:30439-30446
24. Huang WC, Xie Z, Konaka H et al (2005) Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: role of cAMP-dependent protein kinase A signaling pathway. Cancer Res 65:2303-2313
25. Takai H, Nakayama Y, Kim DS et al (2007) Androgen receptor stimulates bone sialoprotein (BSP) gene transcription via cAMP response element and activator protein 1/glucocorticoid response elements. J Cell Biochem 102:240-251
26. Wojtukiewicz MZ, Zacharski LR, Memoli VA et al (1991) Fibrin formation on vessel walls in hyperplastic and malignant prostate tissue. Cancer 67:1377-1383
27. Weisel JW (2005) Fibrinogen and fibrin. Adv Protein Chem 70:247-249
28. Kostka G, Giltay R, Bloch W et al (2001) Perinatal lethality and endothelial cell abnormalities in several vessel compartments of fibulin-1-deficient mice. Mol Cell Biol 21:7025-7034
29. Tran H, Tanaka A, Litvinovich SV et al (1995) The interaction of fibulin-1 with fibrinogen. A potential role in hemostasis and thrombosis. J Biol Chem 270:19458-19464
30. Hao J, Jackson L, Calaluce R et al (2001) Investigation into the mechanism of the loss of laminin 5 (alpha3beta3gamma2) expression in prostate cancer. Am J Pathol 158:1129-1135
31. Quaglia A, Etessami N, Sim R et al (2005) Vascular invasion and herniation by hepatocellular carcinoma in cirrhosis: a wolf in sheep's clothing? Arch Pathol Lab Med 129:639-644
32. Ustach CV, Kim HR (2005) Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells. Mol Cell Biol 25:6279-6288
33. Magee JA, Araki T, Patil S et al (2001) Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 61:5692-5696
34. Klezovitch O, Chevillet J, Mirosevich J et al (2004) Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 6:185-195
35. Usher PA, Thomsen OF, Iversen P et al (2005) Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. Int J Cancer 113:870-880
36. Cozzi PJ, Wang J, Delprado W et al (2006) Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer. Hum Pathol 37:1442-1451
37. Dublin E, Hanby A, Patel NK et al (2000) Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology. Am J Pathol 157:1219-1227
38. Heaton JH, Dlakic WM, Gelehrter TD (2003) Posttranscriptional regulation of PAI-1 gene expression. Thromb Haemost 89:959-966
39. Festuccia C, Angelucci A, Gravina GL et al (2000) Osteoblast-derived TGF-beta1 modulates matrix degrading protease expression and activity in prostate cancer cells. Int J Cancer 85:407-415
40. Unlu A, Leake RE (2003) Transforming growth factor beta1 stimulates urokinase plasminogen activator system on prostate cancer cells. Int J Biol Markers 18:147-151
41. Brantley-Sieders DM, Fang WB, Hwang Y et al (2006) Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by epha receptor and vascular endothelial growth factor in mice. Cancer Res 66:10315-10324
42. Ahmad SA, Liu W, Jung YD et al (2001) Differential expression of angiopoietin-1 and angiopoietin-2 in colon carcinoma. A possible mechanism for the initiation of angiogenesis. Cancer 92:1138-1143
43. Yancopoulos GD, Davis S, Gale NW et al (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242-248
44. Brubaker KD, Brown LG, Vessella RL et al (2006) Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer 6:15
45. Lipton A (2006) Future treatment of bone metastases. Clin Cancer Res 12:6305s-6308s
46. Roudier MP, Corey E, True LD et al (2004) Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases. Cancer Treat Res 118:311-339
47. Bubendorf L, Schopfer A, Wagner U et al (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31:578-583
48. Sikes RA, Nicholson BE, Koeneman KS et al (2004) Cellular interactions in the tropism of prostate cancer to bone. Int J Cancer 110:497-503
49. Cifuentes N, Pickren JW (1979) Metastases from carcinoma of mammary-gland - autopsy study. J Surg Oncol 11:193-205